Waverton Investment Management Ltd increased its position in Blueprint Medicines Corp (NASDAQ:BPMC) by 18.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 14,760 shares of the biotechnology company’s stock after buying an additional 2,260 shares during the quarter. Waverton Investment Management Ltd’s holdings in Blueprint Medicines were worth $1,113,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in BPMC. SG Americas Securities LLC increased its stake in Blueprint Medicines by 23.3% in the 2nd quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 778 shares during the period. Great West Life Assurance Co. Can boosted its holdings in Blueprint Medicines by 53.6% in the 3rd quarter. Great West Life Assurance Co. Can now owns 3,332 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 1,163 shares during the period. Bank of New York Mellon Corp boosted its holdings in Blueprint Medicines by 0.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 176,029 shares of the biotechnology company’s stock valued at $12,264,000 after purchasing an additional 1,326 shares during the period. Rhumbline Advisers lifted its holdings in shares of Blueprint Medicines by 3.0% during the 3rd quarter. Rhumbline Advisers now owns 45,033 shares of the biotechnology company’s stock worth $3,137,000 after acquiring an additional 1,329 shares during the period. Finally, Ameritas Investment Partners Inc. increased its position in shares of Blueprint Medicines by 68.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 1,391 shares in the last quarter. Institutional investors own 83.54% of the company’s stock.
Several equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Blueprint Medicines from a “hold” rating to a “buy” rating and set a $87.00 price objective for the company in a research report on Monday. DA Davidson began coverage on shares of Blueprint Medicines in a research report on Friday, September 29th. They set a “buy” rating and a $90.00 price target for the company. BTIG Research began coverage on shares of Blueprint Medicines in a research note on Friday, September 29th. They set a “buy” rating and a $90.00 price objective on the stock. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a research note on Tuesday, October 31st. Finally, Goldman Sachs Group reaffirmed a “buy” rating and issued a $79.00 price target (up previously from $64.00) on shares of Blueprint Medicines in a research note on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Blueprint Medicines presently has an average rating of “Buy” and an average price target of $84.10.
Blueprint Medicines Corp (NASDAQ BPMC) traded up $3.38 during midday trading on Wednesday, hitting $78.02. 512,300 shares of the stock were exchanged, compared to its average volume of 457,933. The firm has a market capitalization of $3,200.00 and a P/E ratio of -22.81. Blueprint Medicines Corp has a 12 month low of $30.98 and a 12 month high of $92.00. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.02.
Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.06). The firm had revenue of $8.07 million for the quarter, compared to analyst estimates of $5.35 million. Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. Blueprint Medicines’s quarterly revenue was up 31.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.62) earnings per share. sell-side analysts predict that Blueprint Medicines Corp will post -3.75 earnings per share for the current fiscal year.
Blueprint Medicines Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corp (NASDAQ:BPMC).
What are top analysts saying about Blueprint Medicines? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Blueprint Medicines and related companies.